Unilever plans sale of women's health diagnostic subsidiary

Published: 28-Jul-2001


Unilever intends to seek buyers for its women's health diagnostics subsidiary, Unipath Limited, as it continues to focus resource behind selected consumer brands in its 'Path to Growth' Strategy.

Unipath is best known for its Clearblue home pregnancy test and ClearPlan range of home ovulation and fertility monitoring systems, which are global leaders in their respective market sectors, and for the Persona method of contraception distributed in Europe. The company also produces a range of clinical diagnostic products for the medical profession.

Announcing Unilever's intention to sell Unipath, Keki Dadiseth, Unilever director responsible for world-wide home and personal care operations, said, 'Unipath has brought innovative technology to the women's health diagnostics market since its formation in 1984. It is a largely stand-alone business which we believe would benefit from a new parent company, better able to focus on developing its full potential.' Unipath's head office is in Bedford, UK. This is also the sole research, development and manufacturing site for its products and centre of its world-wide sales/distribution network. It employs a total 480 people, of whom around 60 are dedicated to research and development projects.

You may also like